Session conducted by Dr. Rupa
Renganathan, who performed India's first breast cancer cryoablation
procedure with ProSense®; Expert interview with Dr. Hania Bednarski, who has performed cryoablation
breast procedures since 2014
CAESAREA, Israel, Feb. 27,
2024 /PRNewswire/ -- IceCure Medical Ltd.
(Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the
ProSense® System, a minimally-invasive cryoablation technology that
destroys tumors by freezing as an alternative to surgical tumor
removal, today announced ProSense® was featured in a number of
sessions, including one titled "Minimal access imaging guided
therapies: cryoablative therapies in breast pathologies," at
the fourth Breast Imaging & Interventional Techniques
(BRIIT) conference at Tata Memorial Centre in Mumbai, India on February 24, 2024. Breast cryoablation expert Dr.
Hania Bednarksi also joined one session virtually to provide her
valuable experience as a ProSense® user.
ProSense® has regulatory approval and is marketed and sold in
India through IceCure's
distributor, Novomed Ltd.
"We have been very active in India and appreciate Dr. Renganathan's
initiative inleading the cryoablation education section with
ProSense® at BRIIT and Dr. Bednarski for sharing her extensive
experience with ProSense®," stated IceCure CEO Eyal Shamir. "Members of IceCure's clinical and
marketing team were at the conference to support for the education
process and our in-country distributor. We received high levels of
interest in procuring ProSense® systems from doctors, clinics and
hospitals."
Dr. Renganathan commented, "Since the first ProSense® procedure
that I conducted about eight months ago at Kovai Medical Center,
there has been growing global interest in cryoablation. Therefore,
my presentation at BRIIT was well timed, as I was able to share the
benefits of cryoablation with a large number of doctors from around
the country, at Tata Memorial Centre, widely regarded as one of the
leading cancer centers in South
Asia."
"I have been performing breast cryoablation procedures since
2014 and am currently conducting one to three procedures per week
using ProSense® with positive results," stated Dr. Bednarski. "I am
honored to have been asked to share my experiences with my
colleagues in India. Cryoablation
provides clinicians with a new choice in the treatment of breast
tumors, and I'm delighted to support its use around the world."
About ProSense®
The ProSense® Cryoablation System provides a minimally invasive
treatment option to destroy tumors by freezing them. The system
uniquely harnesses the power of liquid nitrogen to create large
lethal zones for maximum efficacy in tumor destruction in benign
and cancerous lesions, including breast, kidney, lung, and
liver.
ProSense® enhances patient and provider value by accelerating
recovery, reducing pain, surgical risks, and complications. With
its easy, transportable design and liquid nitrogen utilization,
ProSense® opens that door to fast and convenient office-based
procedure for breast tumors.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®,
an advanced liquid-nitrogen-based cryoablation therapy for the
treatment of tumors (benign and cancerous) by freezing, with the
primary focus areas being breast, kidney, bone and lung cancer. Its
minimally invasive technology is a safe and effective alternative
to hospital surgical tumor removal that is easily performed in a
relatively short procedure. The system is marketed and sold
worldwide for the indications cleared and approved to date
including in the U.S., Europe, and
China.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. Words such as "expects," "anticipates," "intends,"
"plans," "believes," "seeks," "estimates" and similar expressions
or variations of such words are intended to identify
forward-looking statements. Historical results of scientific
research and clinical and preclinical trials do not guarantee that
the conclusions of future research or trials will suggest identical
or even similar conclusions. Important factors that could cause
actual results, developments and business decisions to differ
materially from those anticipated in these forward-looking
statements include, among others: the Company's planned level of
revenues and capital expenditures; the Company's available cash and
its ability to obtain additional funding; the Company's ability to
market and sell its products; legal and regulatory developments in
the United States and other
countries; the Company's ability to maintain its relationships with
suppliers, distributors and other partners; the Company's ability
to maintain or protect the validity of its patents and other
intellectual property; the Company's ability to expose and educate
medical professionals about its products; political, economic and
military instability in the Middle
East, specifically in Israel; as well as those factors set forth in
the Risk Factors section of the Company's Annual Report on Form
20-F for the year ended December 31,
2022 filed with the SEC on March 29,
2023, and other documents filed with or furnished to the SEC
which are available on the SEC's website, www.sec.gov. The Company
undertakes no obligation to update these statements for revisions
or changes after the date of this release, except as required by
law.
Logo:
https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
IR Contact:
Email:
investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
View original
content:https://www.prnewswire.com/news-releases/fourth-briit-conference-in-india-features-icecures-prosense-in-breast-cancer-imaging--interventions-workshop-302072462.html
SOURCE IceCure Medical